|  | 
          You are here: Home: LCU 1 | 2006 : Faculty disclosures 
 CONTENT VALIDATION   AND DISCLOSURES
 Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-
  the-art education. We assess potential conflicts of interest with faculty, planners and managers of
  CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content
  validation process. The content of each activity is reviewed by both a member of the scientific staff
  and an external independent reviewer for fair balance, scientific objectivity of studies referenced and
patient care recommendations. 
  The scientific staff and consultants for Research To Practice are involved in the development and review
  of content for educational activities and report the following real or apparent conflicts of interest for
  themselves (or their spouses/partners) that have been resolved through a peer review process: Richard
  Kaderman, PhD, Neil Love, MD, Douglas Paley, Michelle Paley, MD, Margaret Peng, Lilliam Sklaver
  Poltorack, PharmD, Carol R Regueiro, MD, MSc and Kathryn Ault Ziel, PhD — no real or apparent
  conflicts of interest to report; Marie Bialek, PharmD — freelancer/contractor: McNeil Consumer
& Specialty Pharmaceuticals, Janssen Pharmaceutica Products LP; salary (spouse): AstraZeneca
Pharmaceuticals LP; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc. Research To Practice
receives education grants from Abraxis Oncology, Amgen Inc, AstraZeneca Pharmaceuticals LP,
Biogen Idec, Genentech BioOncology, Genomic Health Inc, Roche Laboratories Inc and Sanofi-Aventis,
who have no influence on the content development of our educational activities. 
  In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts
  of interest that have been resolved through a peer review process: 
  Dr Lynch — Consulting Fees: Genentech BioOncology, Sanofi-Aventis. Fees for Non-CME Services Received
  Directly from Commercial Interest of their Agents: Genentech BioOncology, Sanofi-Aventis. Dr Albain — No financial
  interests or affiliations to disclose. Dr Gralla — Consulting Fees: Eli Lilly and Company, Genentech BioOncology,
  GlaxoSmithKline, Sanofi-Aventis; Contracted Research: Eli Lilly and Company, Sanofi-Aventis.  
 This educational activity contains discussion of published and/or investigational uses of agents that are
  not indicated by the Food and Drug Administration. Research To Practice does not recommend the use
  of any agent outside of the labeled indications. Please refer to the official prescribing information for each
  product for discussion of approved indications, contraindications and warnings. The opinions expressed
are those of the presenters and are not to be construed as those of the publisher or grantors.  
 
 |  |